Dialyzer from Baxter demonstrates favorable results in improving hemodialysis
An observational multicenter cohort analysis revealed hemodialysis treatment with the Theranova dialyzer from Baxter International Inc. may reduce cardiovascular events by 35% and hospitalization by 18%, according to a press release.
Theranova was designed for hemodialysis (HD) therapy to “filter a wider range of molecules from the blood than traditional HD filters.” Unlike regular dialysis, the release noted that Theranova can remove larger middle molecules that may impact inflammation and cardiovascular health in patients with end-stage renal disease.
“These new findings support a growing library of evidence that kidney disease patients on HDx therapy enabled by Theranova may experience improved clinical outcomes and lower healthcare resource utilization,” Peter Rutherford, MD, senior medical director at Baxter Renal Care, said in the release.
The study followed 1,000 adult patients on HD in Columbia for up to 2 years. The researchers compared patient outcomes with Theranova treatment to outcomes with high-flux HD. The two methods produced similar hospital duration and survival rates. Randomized clinical trials are needed to confirm this trend, according to Baxter.
Theranova is used in the United States under de novo authorization from the FDA. Currently, more than 40 countries use the dialyzer.
Read more about